Sensus Healthcare, Inc. income statement
In fiscal 2025, Sensus Healthcare, Inc. reported revenue of $27.5m, down 34.3% on the year before, operating income of −$10.3m (a -37.5% margin) and net income of −$7.7m, or −$0.47 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.
Income statement
| Fiscal year | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 10 | 15 | 21 | 26 | 27 | 10 | 27 | 45 | 24 | 42 | 27 | 18 |
| Cost of revenue | 4 | 5 | 7 | 10 | 10 | 4 | 10 | 15 | 10 | 17 | 16 | 11 |
| Gross profit | 7 | 10 | 14 | 17 | 18 | 5 | 17 | 30 | 14 | 24 | 12 | 6 |
| Research and development | 1 | 2 | 5 | 6 | 6 | 4 | 3 | 3 | 4 | 4 | 8 | 6 |
| Selling, general and administrative | — | — | — | — | — | — | — | — | 5 | 7 | 8 | 8 |
| Selling and marketing | 4 | 5 | 8 | 9 | 9 | 5 | 5 | 6 | — | — | — | — |
| General and administrative | 2 | 3 | 4 | 4 | 4 | 4 | 5 | 5 | — | — | — | — |
| Operating income | −0 | −0 | −4 | −2 | −2 | −8 | 4 | 15 | −0 | 8 | −10 | −13 |
| Interest expense | 0 | 0 | 0 | 0 | — | 0 | 0 | −0 | −1 | −1 | — | — |
| Net interest income | — | — | — | — | — | — | — | — | — | 1 | 1 | 1 |
| Income before tax | −0 | −0 | — | — | — | — | 4 | 28 | 1 | 9 | −10 | −13 |
| Income tax | — | — | — | — | — | — | — | 4 | 0 | 2 | −2 | 3 |
| Net income | −0 | −0 | −4 | −2 | −2 | −7 | 4 | 24 | 0 | 7 | −8 | −15 |
| Diluted EPS | −$0.08 | −$0.03 | −$0.28 | −$0.14 | −$0.10 | −$0.42 | $0.25 | $1.46 | $0.03 | $0.41 | −$0.47 | −$0.94 |
| Diluted shares (average) | 10m | 12m | 13m | 14m | 16m | 16m | 17m | 17m | 16m | 16m | 16m | 16m |
| EBITDA | 0 | −0 | −3 | −1 | −1 | −8 | 5 | 15 | −0 | 8 | −10 | −13 |
| Quarter | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 9 | 13 | 8 | 7 | 7 | 5 | 3 | 2 |
| Cost of revenue | 4 | 6 | 4 | 4 | 4 | 3 | 2 | 2 |
| Gross profit | 5 | 7 | 4 | 3 | 3 | 2 | 1 | 1 |
| Research and development | 1 | 2 | 3 | 1 | 2 | 2 | 2 | 1 |
| Selling, general and administrative | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Operating income | 1 | 2 | −3 | −2 | −3 | −3 | −4 | −3 |
| Interest expense | — | — | −0 | −0 | — | — | — | — |
| Net interest income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income before tax | 2 | 2 | −2 | −2 | −2 | −3 | −4 | −3 |
| Income tax | 1 | 0 | 0 | −1 | −1 | 0 | −2 | 6 |
| Net income | 1 | 2 | −3 | −1 | −1 | −3 | −3 | −9 |
| Diluted EPS | $0.07 | $0.10 | −$0.16 | −$0.06 | −$0.06 | −$0.19 | −$0.16 | −$0.53 |
| EBITDA | 2 | 2 | −3 | −2 | −2 | −3 | −4 | −3 |
Compare with peers
- Hyperfine, Inc. income statement
- Spectral AI, Inc. income statement
- Jin Medical International Ltd. income statement
- Nephros Inc income statement
- Vivos Therapeutics, Inc. income statement
Head to head: HYPR vs SRTSMDAI vs SRTSSRTS vs ZJYL
More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies